CA-ODASEVA
12.9.2019 14:02:14 CEST | Business Wire | Press release
Odaseva , the unified cloud data protection, compliance and operations platform for enterprises running Salesforce as a business-critical application, today announced that it has seen triple year over year growth, and after only seven years of operation, supports a staggering one trillion Salesforce records, with over 10 million enterprise-level internal Salesforce customers.
Odaseva’s explosive growth is in part due to the influx of new data privacy and governance laws such as GDPR or CCPA , demanding that businesses put in place specific regulations such as Data Subject Rights (which stipulates that consumers have the right to access their own private information) and leverage more robust data governance solutions to shield and manage private customer information. Odaseva, which began in 2012 with one client, Schneider Electric, has rapidly increased its enterprise customer base including Toyota France, Robert Half International and GE, offering organizations the ability to augment their existing cloud data protection solutions.
“Comprehensive compliance automation and data protection are essential for organizations coping with increasingly complex and costly privacy regulations as varied as HIPAA, GDPR, CCPA and PIPEDA,” says Sovan Bin, founder and CEO of Odaseva. “As confidential personal data is often distributed across multiple clouds, as well as on-premises data centers, our goal at Odaseva has been to introduce consistency in how audit information is gathered and presented as well as preserved, in order to provide a measure of relief for businesses striving to comply with multiple regulations.
“No other technology vendor today can offer such a unified cloud data governance suite for Salesforce as Odaseva,” Sovan Bin continued.
Recent Investments and Increased Headcount
In 2019, Odaseva raised $11.7m in Series A funding round, which brought the total funding for Odaseva to $14 million. The round was led by Partech with participation from new investor Salesforce Ventures and existing investor Serena. These new investments have allowed Odaseva to direct a portion of the new funding to build on existing sales and technology partnerships with Accenture, Capgemini, CGI, and Deloitte.
In addition, Odaseva has doubled their headcount in the past six months with new hires including a new chief legal officer and a vice president of customer and partner success.
Located in San Francisco and Paris, Odaseva continues to actively recruit in both locations and is looking to expand its operations globally.
Added New Products to Portfolio Line-up:
The hallmark of Odaseva’s solution lies in its compliance automation tools such as GDPR for Salesforce which allows the enterprise to automate a broad range of data procedures from backup to archival, audit, and more in order to comply with industry regulations.
However in 2019 alone, Odaseva announced several new tools to complete their portfolio that have included the following:
- Cockpit AI: With advanced machine learning capabilities, Cockpit AI offers the first predictive capacity management system to help enterprise Salesforce users maximize the value of the platform by automating the process of monitoring and forecasting the use of platform allocations – such as file storage, data storage and API calls on Salesforce
- Vault: Works with the Odaseva platform to help users automatically archive sensitive data that organizations are required to keep for long periods of time in regulated industries such as financial services, healthcare and insurance. Not only will the information be kept safe from any unauthorized users, but Odaseva ensures a data durability level of 99.999999999% over a given year.
- Full Sandbox Anonymization application (FSA) for Salesforce customers . The application works with the Odaseva platform to anonymize all personal information that an organization may put in a Salesforce Full Sandbox – which is an isolated copy of an organization’s Salesforce environment that can be used for training, development and testing.
About Odaseva
For enterprises that leverage Salesforce as a mission-critical application, Odaseva delivers enterprise-class data governance, providing data protection (backup and recovery, archiving, governor limits monitoring), data compliance for regulation requirements such as GDPR and data operations (Salesforce DX data extensions). Odaseva was engineered for Salesforce by Salesforce experts and is endorsed by Salesforce Ventures. Over 10+Million Salesforce Enterprise users from industry-leading companies such as Schneider Electric, Heineken and Robert Half trust Odaseva’s data governance platform.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005206/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
